Pictet Asset Management
MLTX icon

Pictet Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Pictet Asset Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-131,991
Closed -$946K – 2108
2025
Q3 		$946K Sell
131,991
-15,730
-11% -$820K ﹤0.01% 1084
2025
Q2 		$6.97M Sell
147,721
-174,393
-54% -$7.1M 0.01% 729
2025
Q1 		$12.6M Sell
322,114
-24,503
-7% -$1.06M 0.01% 601
2024
Q4 		$18.8M Sell
346,617
-10,219
-3% -$522K 0.02% 520
2024
Q3 		$18M Buy
356,836
+10,996
+3% +$515K 0.02% 517
2024
Q2 		$15.2M Sell
345,840
-154,001
-31% -$6.52M 0.02% 540
2024
Q1 		$25.1M Sell
499,841
-116,722
-19% -$6.33M 0.03% 440
2023
Q4 		$37.2M Buy
616,563
+74,662
+14% +$3.85M 0.04% 357
2023
Q3 		$30.9M Buy
+541,901
New +$29.9M 0.04% 363

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Pictet Asset Management's MLTX Position: Q4 2025 in Review

Pictet Asset Management sold out of MoonLake Immunotherapeutics (MLTX) in Q4 2025, closing a stake of 131,991 shares — an estimated $946K sold.

Pictet Asset Management first reported a position in MLTX in Q3 2023 and held it in 9 quarters. The position peaked at $37.2M in Q4 2023. 130 funds tracked by Wall St. Rank hold MLTX as of Q4 2025.

  • Pictet Asset Management reported no remaining MoonLake Immunotherapeutics position as of Q4 2025 after selling out during the quarter.
  • Pictet Asset Management sold 131,991 MoonLake Immunotherapeutics shares in Q4 2025, an estimated $946K.
  • Pictet Asset Management first reported a position in MoonLake Immunotherapeutics in Q3 2023 and held it in 9 quarters.
  • Pictet Asset Management's MoonLake Immunotherapeutics position peaked at $37.2M in Q4 2023.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q4 2025.

Based on Pictet Asset Management's 13F filing for Q4 2025, filed 29 Jan 2026.